Single gene targeted nanopore sequencing enables simultaneous identification and antimicrobial resistance detection of sexually transmitted infections

PLoS One. 2022 Jan 21;17(1):e0262242. doi: 10.1371/journal.pone.0262242. eCollection 2022.

Abstract

Objectives: To develop a simple DNA sequencing test for simultaneous identification and antimicrobial resistance (AMR) detection of multiple sexually transmitted infections (STIs).

Methods: Real-time PCR (qPCR) was initially performed to identify Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) infections among a total of 200 vulvo-vaginal swab samples from female sex workers in Ecuador. qPCR positive samples plus qPCR negative controls for these STIs were subjected to single gene targeted PCR MinION-nanopore sequencing using the smartphone operated MinIT.

Results: Among 200 vulvo-vaginal swab samples 43 were qPCR positive for at least one of the STIs. Single gene targeted nanopore sequencing generally yielded higher pathogen specific read counts in qPCR positive samples than qPCR negative controls. Of the 26 CT, NG or MG infections identified by qPCR, 25 were clearly distinguishable from qPCR negative controls by read count. Discrimination of TV qPCR positives from qPCR negative controls was poorer as many had low pathogen loads (qPCR cycle threshold >35) which produced few specific reads. Real-time AMR profiling revealed that 3/3 NG samples identified had gyrA mutations associated with fluoroquinolone resistance, 2/10 of TV had mutations related to metronidazole resistance, while none of the MG samples possessed 23S rRNA gene mutations contributing to macrolide resistance.

Conclusions: Single gene targeted nanopore sequencing for diagnosing and simultaneously identifying key antimicrobial resistance markers for four common genital STIs shows promise. Further work to optimise accuracy, reduce costs and improve speed may allow sustainable approaches for managing STIs and emerging AMR in resource poor and laboratory limited settings.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • DNA Gyrase / genetics
  • Drug Resistance, Bacterial / genetics*
  • Ecuador
  • Female
  • Fluoroquinolones / pharmacology
  • Fluoroquinolones / therapeutic use
  • Humans
  • Macrolides / pharmacology
  • Mycoplasma genitalium / drug effects
  • Mycoplasma genitalium / genetics*
  • Mycoplasma genitalium / isolation & purification
  • Nanopore Sequencing
  • Neisseria gonorrhoeae / drug effects
  • Neisseria gonorrhoeae / genetics*
  • Neisseria gonorrhoeae / isolation & purification
  • RNA, Ribosomal, 23S / chemistry
  • RNA, Ribosomal, 23S / genetics
  • RNA, Ribosomal, 23S / metabolism
  • Real-Time Polymerase Chain Reaction
  • Sex Workers
  • Sexually Transmitted Diseases / diagnosis*
  • Sexually Transmitted Diseases / drug therapy
  • Sexually Transmitted Diseases / microbiology
  • Trichomonas vaginalis / drug effects
  • Trichomonas vaginalis / genetics*
  • Trichomonas vaginalis / isolation & purification
  • Vagina / microbiology

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Macrolides
  • RNA, Ribosomal, 23S
  • DNA Gyrase

Grants and funding

1) Wellcome Trust 204809/Z/16/Z to St. George’s, University of London, Syed Tariq Sadiq 2) UIDE UIDE-EDM04-2016-2017 Natalia Romero Sandoval.